NurExone Biologic Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

TSXV:NRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Dec 24SellCA$17,187James RichardsonIndividual22,000CA$0.80
05 Dec 24SellCA$9,258James RichardsonIndividual13,000CA$0.72
01 Nov 24BuyCA$27,500James RichardsonIndividual50,000CA$0.55
27 Sep 24SellCA$3,705James RichardsonIndividual6,500CA$0.57
25 Sep 24SellCA$2,850James RichardsonIndividual5,000CA$0.57
24 Sep 24SellCA$3,648James RichardsonIndividual6,400CA$0.57
20 Sep 24SellCA$2,860James RichardsonIndividual5,000CA$0.58
13 Sep 24SellCA$2,950James RichardsonIndividual5,000CA$0.59
12 Sep 24SellCA$2,320James RichardsonIndividual4,000CA$0.58
11 Sep 24SellCA$2,850James RichardsonIndividual5,000CA$0.57
10 Sep 24SellCA$1,160James RichardsonIndividual2,000CA$0.58
09 Sep 24SellCA$2,320James RichardsonIndividual4,000CA$0.58
09 Sep 24SellCA$1,160James RichardsonIndividual2,000CA$0.58
04 Sep 24SellCA$2,400James RichardsonIndividual4,000CA$0.60
04 Sep 24SellCA$2,520James RichardsonIndividual4,000CA$0.63
18 Jun 24SellCA$13,100James RichardsonIndividual20,000CA$0.66
18 Jun 24SellCA$36,750James RichardsonIndividual49,000CA$0.75
17 Jun 24SellCA$8,835James RichardsonIndividual15,500CA$0.57
14 Jun 24SellCA$2,565James RichardsonIndividual4,500CA$0.57
06 Jun 24SellCA$7,920James RichardsonIndividual16,000CA$0.49

Insider Trading Volume

Insider Buying: NRX insiders have sold more shares than they have bought in the past 3 months.


Ownership Breakdown

What is the ownership structure of NRX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,739,1336.68%
General Public66,154,46593.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.9%.


Top Shareholders

Top 4 shareholders own 6.68% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.16%
Yoram Drucker
3,655,000CA$2.6m0%no data
0.6%
Lior Shaltiel
425,000CA$297.5k0%no data
0.6%
Eran Ovadya
425,000CA$297.5k0%no data
0.33%
James Richardson
234,133CA$163.9k6.85%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NurExone Biologic Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley SorensenZacks Small-Cap Research